PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma

Despite increasing incidence, treatment for hepatoblastoma has not changed significantly over the past 20 years. Chemotherapeutic strategies continue to rely on cisplatin, as it remains the most active single agent against hepatoblastoma. However, chemoresistance remains a significant challenge with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Sci Rep
Main Authors: Marayati, Raoud, Stafman, Laura L., Williams, Adele P., Bownes, Laura V., Quinn, Colin H., Aye, Jamie M., Stewart, Jerry E., Yoon, Karina J., Anderson, Joshua C., Willey, Christopher D., Beierle, Elizabeth A.
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7966748/
https://ncbi.nlm.nih.gov/pubmed/33727604
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-85289-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados